Shopping Cart
Remove All
Your shopping cart is currently empty
Pyridoclax is an inhibitor of potential Mcl-1.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $82 | 5 days | 5 days |
| Description | Pyridoclax is an inhibitor of potential Mcl-1. |
| In vitro | Pyridoclax directly binds to Mcl-1. Pyridoclax induces apoptosis in combination with Bcl-xL-targeting siRNA or with ABT-737 in ovarian, lung, and mesothelioma cancer cells. Pyridoclax causes apoptosis in ovarian, and also in lung, and mesothelioma cancer cells when it is administrated in combination with Bcl-xL-targeting siRNA or Bcl-xL targeting molecules such as ABT-737 or its orally available derivative ABT-263. Pyridoclax sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies [1][2]. |
| Synonyms | MR-29072 |
| Molecular Weight | 426.51 |
| Formula | C29H22N4 |
| Cas No. | 1651890-44-6 |
| Smiles | Cc1cc(cnc1-c1cccnc1)-c1ncc(cc1\C=C\c1ccccc1)-c1cccnc1 |
| Relative Density. | 1.192 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 20 mg/mL (46.89 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.